This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Thrombocytosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Thrombocytosis occurs when the platelet count exceeds 450 x 10^9/l although numbers may exceed 1,000 x 10^9/l without symptoms.

Thrombosis and paradoxically, haemorrhage are the main symptoms but their occurrence is as much dependent on qualitative defects in the platelets as much as their number.

Two types of thrombocytosis are recognised:

  • reactive thrombocytosis - for which the term thrombocytosis is properly reserved
  • thrombocythaemia - an autonomous or essential thrombocytosis

A suggested management pathway in adults:

 

Notes:

  • in routine clinical practice, reactive thrombocytosis may be responsible for more than 85% of cases with an increased platelet count
    • causes of reactive thrombocythaemia (including inflammation, infection, haemorrhage and iron deficiency) must be excluded before a diagnosis of essential thrombocythaemia (ET)
    • any degree of persistent thrombocytosis, whether or not it fulfils the conventional criterion of being above 600×109/l, must be pursued for the possible diagnosis of ET
  • cases of unexplained thrombocytosis in adults may be due to cancer - consider further investigations such as a CXR, and OGD and faecal immunochemical test (FIT)

Reference:

  1. Skoda RC. Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009:159-67

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.